| abstract |
The present invention provides a method for the treatment or prophylaxis of benign prostatic hyperplasia or prostatic cancer in a patient in need of such treatment comprising administering a selective estrogen receptor modulating compound of formula (I), in which R1 and R2 are independently hydroxy and alkoxy of one to four carbon atoms; and R3 and R4 are independently methyl or ethyl, or R3 and R4, taken together with the nitrogen atom to which they are attached, form a pyrrolidino, methyl-pyrrolidino, dimethylpyrrolidino, piperidino, morpholino, or hexamethyleneimino ring. |